Novo Nordisk's obesity drug Wegovy, in tablet form, reached 38,220 prescriptions in the US during the fifth week of sales following its launch. The figure refers only to week five and is not cumulative. This is according to IQVIA data reviewed by Reuters.

The number provides an early indication of demand for the company's new oral weight loss treatment.

The same data source showed just over 26,000 prescriptions during the second full week after launch, as previously reported by Finwire.

Barclays at the time described this as a very strong launch.

At the beginning of February, Hims & Hers Health announced they would offer a copy of Novo Nordisk's new Wegovy in tablet form, a move that put pressure on the Danish pharmaceutical company's stock. However, Hims & Hers later announced on X that they were withdrawing the copy.